Travere Therapeutics, Inc. (NASDAQ: TVTX) recently saw notable insider activity from its executive leadership. Jula Inrig, serving as the Chief Medical Officer, executed multiple transactions involving company common stock over a three-day period in early May 2026. The total value of the shares sold during this window reached approximately $1,015,085, encompassing 22,485 shares.
Detailed Breakdown of Insider Transactions
The selling activity was spread across three consecutive days, utilizing different execution methods:
- May 4, 2026: Ms. Inrig sold 20,000 shares at a price point of $45.00 per share. This specific sale was carried out under a Rule 10b5-1(c) trading plan that had been established on May 28, 2025.
- May 5, 2026: A sale of 2,174 shares occurred at $46.65 per share. This was a non-discretionary "sell to cover" transaction, required to meet tax withholding obligations stemming from the vesting of performance-based restricted stock units (PSUs).
- May 6, 2026: An additional 311 shares were sold at $43.95 per share. Similar to the May 5 activity, this sale was conducted through a Rule 10b5-1(c) plan adopted on May 28, 2025, and included portions intended to cover tax obligations related to vested performance restricted stock units.
Prior to these sales, Ms. Inrig engaged in several acquisition activities. On May 4, she acquired 20,000 shares of common stock by exercising employee stock options at an exercise price of $22.40 per share. Furthermore, on that same day, 4,250 shares vested from performance-based restricted stock units. These specific PSUs were originally granted on January 31, 2024, and their vesting was tied to meeting a performance criterion involving cumulative net revenue for FILSPARI. During this reporting period, the total value of shares acquired through PSU vesting and option exercises reached $448,000, with acquisition prices ranging from $0.00 to $22.40 per share.
Market Context and Financial Position
These insider transactions take place during a period of significant market movement for Travere Therapeutics. The company's stock has experienced a 121% surge over the past year. At the time of these reports, the stock was trading at $44.77, approaching its 52-week high of $48.61, with a total market capitalization of $4.16 billion. Analysis suggests that despite being near recent highs, the stock may be undervalued relative to its Fair Value.
The company maintains a "GOOD" financial health score, bolstered by a strong current ratio of 3.13 and a substantial revenue growth rate of 96% over the preceding twelve months. Looking toward future profitability, analysts have projected that the company will reach profitable status this year, with an estimated earnings per share (EPS) of $1.92 for 2026.
Recent Financial Performance and Strategic Funding
The current window of insider activity follows a mixed first-quarter 2026 financial report from Travere Therapeutics. The company reported an EPS of -$0.40, which fell short of the anticipated -$0.23 forecast. Additionally, revenue for the quarter was $127.2 million, missing the expected $137.34 million.
To manage financial requirements and strategic goals, Travere is moving forward with a plan to raise $400 million via a convertible senior notes offering due in 2032. These notes will be senior unsecured obligations featuring semiannual interest payments. The company has also provided underwriters with a 30-day option to purchase an additional $60 million in notes to account for over-allotments.
Current Holdings
Following the reported transactions, Ms. Inrig's direct holdings in Travere Therapeutics common stock stand at 113,238 shares. Her total equity position also includes 34,500 shares held via employee stock options and 4,250 performance-based restricted stock units.